The Hepatitis C Genotype 1 Paradox: Cost per Treatment Is Increasing, but Cost per Cure Is Decreasing

Significant attention has been focused on the perceived increase in the cost of antiviral treatment for hepatitis C genotype 1 infection since the approval of the first direct-acting antiviral agents in 2011. Using Canadian list prices, the present analysis points out a paradox: while the cost per a...

Full description

Saved in:
Bibliographic Details
Main Author: Stephen D Shafran
Format: Article
Language:English
Published: Wiley 2015-01-01
Series:Canadian Journal of Gastroenterology and Hepatology
Online Access:http://dx.doi.org/10.1155/2015/216395
Tags: Add Tag
No Tags, Be the first to tag this record!